Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from MAIA Biotechnology, Inc. ( (MAIA) ) is now available.
On December 11, 2025, MAIA Biotechnology, Inc. announced significant insider buying by its leadership, including CEO Dr. Vlad Vitoc, who acquired 182,445 shares in late November 2025. This insider activity, alongside encouraging clinical results from their telomere-targeting cancer therapy, ateganosine, signals strong confidence in the company’s strategy and potential for long-term value creation. The company also announced the dosing of the first patient in the THIO-104 Phase 3 pivotal trial, marking a critical step in evaluating ateganosine as a third-line treatment for advanced non-small cell lung cancer. These developments are seen as pivotal for MAIA’s positioning in the oncology market and its potential impact on stakeholders.
The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.
Spark’s Take on MAIA Stock
According to Spark, TipRanks’ AI Analyst, MAIA is a Neutral.
MAIA Biotechnology presents a mixed outlook. The company’s financial performance is weak due to its development-stage status and lack of revenue, contributing to a low financial performance score. However, recent positive trial results and technical indicators showing short-term upward momentum provide a more optimistic view. Valuation remains challenging due to negative earnings, but the potential for significant clinical advancements offers upside potential.
To see Spark’s full report on MAIA stock, click here.
More about MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. is a targeted therapy and immuno-oncology company focused on developing and commercializing potential first-in-class drugs with novel mechanisms of action aimed at improving and extending the lives of cancer patients. Their lead program, ateganosine (THIO), is a cancer telomere targeting agent in clinical development for treating non-small cell lung cancer (NSCLC) patients with telomerase-positive cancer cells.
Average Trading Volume: 630,526
Technical Sentiment Signal: Sell
Current Market Cap: $49.99M
For an in-depth examination of MAIA stock, go to TipRanks’ Overview page.